Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lifecore inks biomaterial deal:

This article was originally published in Clinica

Executive Summary

Lifecore Biomedical has entered into exclusive licence and development agreements with the Cleveland Clinic, in Ohio, to develop and commercialise hyaluronan-based products and related applications. It has licensed a patented hyaluronan-based cross-linking technology that can be used for products in aesthetics, orthopaedics, ophthalmology and other medical fields. The biomaterial is formed through a chemical reaction, catalysed by a naturally occurring molecule, which provides a spectrum of formulations that are stable, well-tolerated by the body, and able to mimic the function of a wide variety of tissues, while providing for tissue repair and reinforcement, said the Chaska, Minnesota firm. Lifecore believes the technology platform will allow it to expand in its existing markets and enter new markets.

You may also be interested in...

Common Regulatory Starting Point Means EU-UK Are On Track For Medtech MRA, Say German Firms

With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.

COVID-19 Vaccines Donated To Philippines Require Emergency Use Authorization

Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.

Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders

Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts